Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (PBYI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PBYI · as of Sep 30, 2025
Ownership Breakdown
138
Institutional Holders
▲ 14 vs Q2
$182.74M
Total Inst. Value
▲ $70.16M vs Q2
50.90M
Shares Outstanding
freeFloat 76.80%
34.42M
13F Shares Held
▲ 1.60M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PBYI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ACORN CAPITAL ADVISORS, LLC pharmaceutical preparations | 4.13M | 8.31% | 8.31% | $21.94B | Nov 17, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 3.69M | 7.43% | 7.43% | $19.60B | Nov 7, 2025 | ▼ 14.7K |
BLACKROCK, INC. pharmaceutical preparations | 3.58M | 7.20% | 7.20% | $19.00B | Nov 12, 2025 | ▼ 257.8K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 2.15M | 4.33% | 4.33% | $11.42B | Nov 13, 2025 | ▲ 276.5K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 2.05M | 4.13% | 4.13% | $10.90B | Nov 13, 2025 | ▲ 45.2K |
AMERICAN CENTURY COMPANIES INC pharmaceutical preparations | 1.48M | 2.98% | 2.98% | $7.88B | Nov 12, 2025 | ▲ 140.9K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 1.27M | 2.56% | 2.56% | $6.75B | Nov 12, 2025 | ▲ 121.8K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 983.5K | 1.98% | 1.98% | $5.22B | Nov 12, 2025 | ▲ 11.8K |
RUSSELL INVESTMENTS GROUP, LTD. pharmaceutical preparations | 964.7K | 1.94% | 1.94% | $5.12B | Nov 13, 2025 | ▲ 964.7K |
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. pharmaceutical preparations | 943.5K | 1.90% | 1.90% | $5.01B | Nov 13, 2025 | ▲ 43.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+4.15M shares3
New Positions
first time holders14
Decreased
−1.10M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.05M
+4.15M / −1.10M
Net new holders
+16
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PBYI insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
6
Sell transactions
1.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
AUERBACH ALAN H President and CEO | Feb 18, 2026 | Award | 159,778 | — | — | 7.31M | Form 4 ↗ |
AUERBACH ALAN H President and CEO | Feb 18, 2026 | Award | 227,474 | $6.68 | $1.52M | 227.5K | Form 4 ↗ |
HUNT DOUGLAS M See Remarks | Feb 18, 2026 | Award | 49,394 | — | — | 205.3K | Form 4 ↗ |
HUNT DOUGLAS M See Remarks | Feb 18, 2026 | Award | 70,321 | $6.68 | $469.7K | 70.3K | Form 4 ↗ |
NOUGUES MAXIMO F Chief Financial Officer | Feb 18, 2026 | Award | 46,739 | — | — | 240.0K | Form 4 ↗ |
NOUGUES MAXIMO F Chief Financial Officer | Feb 18, 2026 | Award | 66,541 | $6.68 | $444.5K | 66.5K | Form 4 ↗ |
AUERBACH ALAN H President and CEO | Jan 6, 2026 | Sale | 16,938 | $5.84 | $99.0K | 7.16M | Form 4 ↗ |
AUERBACH ALAN H President and CEO | Jan 7, 2026 | Sale | 18,012 | $5.88 | $105.9K | 7.15M | Form 4 ↗ |
HUNT DOUGLAS M See Remarks | Jan 6, 2026 | Sale | 3,973 | $5.84 | $23.2K | 160.9K | Form 4 ↗ |
HUNT DOUGLAS M See Remarks | Jan 7, 2026 | Sale | 5,014 | $5.88 | $29.5K | 155.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Puma Biotechnology, Inc. (PBYI) is primarily owned by institutional investors, who hold approximately 67.6% of total shares outstanding. Company insiders own approximately 23.20%, while retail and public investors account for the remaining 9.18%.
The largest institutional shareholder of Puma Biotechnology, Inc. is ACORN CAPITAL ADVISORS, LLC, holding approximately 4.13 million shares — equal to 8.31% of outstanding shares — as of September 30, 2025.
A total of 138 institutional investors currently hold PBYI stock, with a combined institutional value of approximately $182,742,457 as of the most recent 13F filing period.
Frequently asked questions
PBYI ownershipPuma Biotechnology, Inc. (PBYI) is primarily owned by institutional investors, who hold approximately 67.6% of shares. The largest shareholder is ACORN CAPITAL ADVISORS, LLC with a 8.31% stake. Company insiders hold 23.20%. Data sourced from SEC Form 13F as of September 30, 2025.